info-chinese
[Top][All Lists]
Advanced

[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[Info-chinese] Stock promotion up to 300% in price


From: Gwen Echols
Subject: [Info-chinese] Stock promotion up to 300% in price
Date: Fri, 22 Sep 2006 14:55:52 -0120

HOT STOCK ALERT - THIS ONE IS STILL CLIMBING THE STOCK CHARTS
ALERT --  BREAKING MARKET NEWS REPORT ----  HLUN.PK


Company Name: HEALTHEUNIVERSE INC
Lookup: HLUN.PK
Current Price: $.16
Expected: STEADILY CLIMB FOR THE TOP
EXPECTATION: MAX!!!!


Breaking News: Healtheuniverse Signs Clinical Research and Marketing Agreement With The California Institute of Cosmetic and Reconstructive Surgery for Fat Based Stem Cell Technology and Products


COVINA, CA--(MARKET WIRE)--Sep 11, 2006 -- Healtheuniverse, Inc., a diversified biotechnology development firm specializing in the development and commercialization of patented biopharmaceutical and biomedical products, announced today that it has entered into an agreement with The California Institute of Cosmetic and Reconstructive Surgery (C.I.C.R.S.) for clinical research, marketing and distribution rights for fat based stem cell technology and products in the United States. The agreement provides for CICRS to conduct clinical trials in the United States for fat based stem cell applications in the areas of cosmetic, plastic, and reconstructive surgery. CICRS grants Healtheuniverse patent, technology, IP, and licensing rights to market and sell products developed by these clinical trials, if they are
approved for marketing.


Under the terms of this agreement, CICRS will manage a series of clinical trials intended to examine the safety and efficacy of fat based stem cell therapies for the treatment of cosmetic, plastic, and reconstructive patients. Healtheuniverse will be responsible for managing and funding the clinical trials and all necessary regulatory registrations for products in the United States. Upon regulatory approval of the products, Healtheuniverse will be the exclusive distributor of products cleared for marketing. Financial terms of the agreement were not disclosed.


About HLUN.PK
HEALTHeUNIVERSE Inc. is a biotechnology development firm specializing in the
development and commercialization of patented Biopharmaceutical and Biomedical
products. We are engaged in research and development of regenerative medicine
therapies using non-embryonic adult stem cells for use in plastic, reconstructive, orthopedic, vascular, and cardiac surgery. Healtheuniverse strives to be the first to commercialize the use of regenerative medicine in plastic and reconstructive surgery and to develop therapeutic uses in the most profitable commercial applications. More information on Healtheuniverse is available online at www.healtheuniverse.com


WATCH THIS STOCK GO HIGHER AND HIGHER


Disclaimer:
Information within this email contains "forward looking statements" within the meaning of Section 27(a) of the Securities act of 1933 and Section 21B of the Securities exchange act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives,goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." The publisher of this newsletter advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice or offer to sell or solicitation of an offer to buy securities. You can lose all your money by investing in this stock. In compliance with the Securities act of 1933, Section 17(b), the publisher of this newsletter discloses they received payment from an unaffiliated third party for the circulation of this report in the amount of twenty thousand dollars. Be aware of an inherent conflict of interest resulting from such compensation due to the fact that this is a paid advertisement and is not without bias. As we have received compensation in the form of free trading securities, we may directly benefit from any increase in the price of these securities. Use of the material within this email constitutes your acceptance of
these terms.







reply via email to

[Prev in Thread] Current Thread [Next in Thread]